A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 25 May 2017
At a glance
- Drugs MK 8242 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 27 Feb 2017 Results published in the Journal of Clinical Oncology
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 06 Jan 2015 Planned End Date changed from 1 Aug 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.